经心房途径经导管二尖瓣置换术应用趋势与术后结局的全国性分析
基于美国胸外科医师学会数据库2014至2021年222例因二尖瓣环钙化行经心房途径经导管二尖瓣置换术的患者,比较早期(2014-2017年,71例)与近期(2018-2021年,151例)的结局。
要点
- 年手术量从2014年6例增至2021年43例,共104家医院开展。
- 近期组手术死亡率3.3%,显著低于早期组25.4%(P<.001)。
- 近期组主要不良心脏事件18.5%,早期组31.0%(P=.057)。
核心结论
- 当代经心房途径经导管二尖瓣置换术后的死亡率和主要不良心脏事件显著下降,且独立于主要患者和手术特征的变化。
- 经心房途径经导管二尖瓣置换术未来将在二尖瓣环钙化患者中发挥作用。
研究设计与样本
- 回顾性分析美国胸外科医师学会数据库2014至2021年因二尖瓣环钙化行经心房途径经导管二尖瓣置换术的患者。
- 排除肥厚型心肌病、先天性二尖瓣疾病、心室辅助装置置入或既往二尖瓣手术者。
- 比较早期(2014-2017年,N=71)与近期(2018-2021年,N=151)两个时代。
- 采用简约多变量回归分析主要不良心脏事件趋势的混杂因素。
主要发现
- 共识别222例经心房途径经导管二尖瓣置换术,分布于104家医院。
- 年手术量从2014年6例增至2021年43例;医院中位手术量1例,最大17例,4家医院完成10例及以上。
- 总体死亡率和主要不良心脏事件发生率分别为10.4%和22.5%。
- 近期组择期手术比例79.5% vs 早期组64.8%,经胸骨途径比例90.1% vs 80.3%(均P<.05)。
- 两组预测死亡风险相似(9.6%±11.1% vs 11.0%±6.0%;P=.61)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Transatrial transcatheter mitral valve replacement reduces complexity during mitral valve replacements involving high-risk patients with mitral annular calcification. This study examines trends in transatrial transcatheter mitral valve replacement use and outcomes. METHODS: Patients in the Society of Thoracic Surgeons database from 2014 to 2021 with mitral annular calcification undergoing transatrial transcatheter mitral valve replacement were included. Exclusion criteria were hypertrophic cardiomyopathy, congenital mitral valve disease, ventricular assist device placement, or prior mitral valve surgery. Primary outcomes were operative mortality and major adverse cardiac events compared between the Early (2014-2017, N = 71) and Recent (2018-2021, N = 151) eras. Parsimonious multivariable regression assessed select possible confounders for trends in major adverse cardiac events. RESULTS: Overall, 222 transatrial transcatheter mitral valve replacements at 104 hospitals were identified. Annual volume increased from 6 in 2014 to 43 in 2021. Median hospital volume was 1, maximum hospital volume was 17, and 10 or more replacements were performed at 4 hospitals. Mortality and major adverse cardiac events occurred in 10.4% and 22.5% of patients, respectively. Compared with the Early era patients, Recent era patients were more often elective (79.5% vs 64.8%) and were approached via sternotomy (90.1% vs 80.3%, all P < .05). Despite similar predicted risk of mortality (9.6% ± 11.1% vs 11.0% ± 6.0%; P = .61), Recent patients had reduced mortality (3.3% vs 25.4%, P < .001) and major adverse cardiac events (18.5% vs 31.0%; P = .057). On univariate and multivariable analyses, the Recent surgical era was significantly associated with lower mortality (0.10 [0.04-0.29]; P < .001) and lower major adverse cardiac events (0.48 [0.25-0.94]; P = .032), respectively. There were no preoperative characteristics that were significant confounders for the difference in major adverse cardiac events. CONCLUSIONS: Mortality and major adverse cardiac events after transatrial transcatheter mitral valve replacement have decreased significantly in the contemporary era independent of changes in major patient and operative characteristics. Transatrial transcatheter mitral valve replacement will have a future role in patients with mitral annular calcification.
引用
- Awtry JA, Shi WY, McGurk S, et al. National trends in utilization of transatrial transcatheter mitral valve replacement and postoperative outcomes. J Thorac Cardiovasc Surg. 2023. PMID: 37839658. doi:10.1016/j.jtcvs.2023.10.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。